Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TARGET: Tenofovir PK for Adherence
NCT03012607Phase 1Completed
- Sponsor
- University of Washington
- Start
- Jan 2017
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tenofovir disoproxil fumarate in human immunodeficiency virus infection (HIV) (3 arms), sponsored by University of Washington. Primary endpoint: Area under the plasma concentration versus time curve at 72 hours. Started Jan 2017; status: completed.
02
Drugs
tenofovir disoproxil fumarate
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03012607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03012607.